Hot Topics: Depression in Individuals With Psoriasis and Psoriatic Arthritis

被引:1
作者
Goel, Niti [1 ,2 ]
Wallace, Elizabeth B. [3 ]
Lindsay, Christine [4 ]
机构
[1] Duke Univ Sch Med, Caduceus Biomed Consulting LLC, Durham, NC USA
[2] Duke Univ Sch Med, Dept Med, Div Rheumatol, Durham, NC USA
[3] Cherry Hills Dermatol, Englewood, CO USA
[4] Patient Res Partner, Prosper, TX USA
关键词
comorbidity; depression; GRAPPA; psoriasis; psoriatic arthritis; PATIENT-REPORTED OUTCOMES; SEVERE PLAQUE PSORIASIS; QUALITY-OF-LIFE; ORAL PHOSPHODIESTERASE-4 INHIBITOR; TO-SEVERE PSORIASIS; PHASE-III; DOUBLE-BLIND; NAIVE PATIENTS; MODERATE; PLACEBO;
D O I
10.3899/jrheum.2024-0362
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Psoriasis and psoriatic arthritis are associated with an increased risk of mental health conditions such as depression and anxiety. People with psoriatic disease (PsD) are also more likely to die by suicide than those without. Mood disorders affect people with PsD in a multitude of ways, such as in effectiveness of care, response to treatment, remission rates, and quality of life. Although the links between PsD and mental health conditions have not been fully elucidated, this review will highlight recent studies investigating shared biologic mechanisms between depression and PsD. Since mental health disorders can be assessed and treated effectively, dermatologists and rheumatologists should be aware of the mental health burden in individuals with PsD to accomplish the following: (1) educate their patients with PsD about this association, (2) screen for mental health conditions on an ongoing basis in their clinical practice, (3) refer their patients with PsD to a mental health professional when needed, and (4) ensure selection of a safe PsD treatment in the setting of comorbid mental health disease. Finally, important treatment considerations for individuals with PsD and depression are reviewed. This topic was presented at the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2023 annual meeting.
引用
收藏
页码:43 / 50
页数:8
相关论文
共 88 条
[1]  
Amgen Inc.., Apremilast (US prescribing information)
[2]  
[Anonymous], [33] European Medicines Agency. Resumo das Caracteristicas do Medicamento (Anexo I). In Mysimba: Cloridrato de Naltrexona+Cloridrato de Bupropiom. 2020 [acedido a 2 de junho de 2022]. Disponivel em: https://www.ema.europa.eu/en/documents/product-information/mysimba-epar-productinformation_pt.pdf
[3]  
[Anonymous], Clinical review report: guselkumab (Tremfya)
[4]  
[Anonymous], Clinical review report: tildrakizumab (Ilumya)
[5]   Pathophysiology, Clinical Presentation, and Treatment of Psoriasis A Review [J].
Armstrong, April W. ;
Read, Charlotte .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2020, 323 (19) :1945-1960
[6]   Effect of Risankizumab on Patient-Reported Outcomes in Moderate to Severe Psoriasis The UltIMMa-1 and UltIMMa-2 Randomized Clinical Trials [J].
Augustin, Matthias ;
Lambert, Jo ;
Zema, Carla ;
Thompson, Elizabeth H. Z. ;
Yang, Min ;
Wu, Eric Q. ;
Garcia-Horton, Viviana ;
Geng, Ziqian ;
Valdes, Joaquin M. ;
Joshi, Avani ;
Gordon, Kenneth B. .
JAMA DERMATOLOGY, 2020, 156 (12) :1344-1353
[7]  
Bausch Health USA LLC.., Brodalumab (US prescribing information)
[8]   Promoting patient-centred care in psoriatic arthritis: a multidisciplinary European perspective on improving the patient experience [J].
Betteridge, N. ;
Boehncke, W-H. ;
Bundy, C. ;
Gossec, L. ;
Gratacos, J. ;
Augustin, M. .
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 (04) :576-585
[9]  
Blizniewska-Kowalska K., 2023, J. Affect. Disord. Rep., V14, DOI [DOI 10.1016/J.JADR.2023.100610, 10.1016/j.jadr.2023.100610]
[10]  
Canadian Agency for Drugs and Technologies in Health., Bimekizumab (Bimzelz)